Latest: FDA Approves New Biosimilar for Oncology Treatment
Oncology

FDA Accepts New Drug Application for Gedatolisib in PIK3CA Wild-Type Breast Cancer

by Cancer Network
0 Comments
0 Mins
The rolling submission is supported by data from the PIK3CA wild-type cohort of the phase 3 VIKTORIA-1 trial evaluating gedatolisib in advanced breast cancer.
Tags:
Cancer Network
Author

Cancer Network

Previous Post
OEM Toll Processing Elevates High-Value Products
Next Post
Similar outcomes between lactated Ringer’s and normal saline for hospitalized patients
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago